These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32246264)

  • 1. Inhalation Therapy for Stable COPD: 20 Years of GOLD Reports.
    Terry PD; Dhand R
    Adv Ther; 2020 May; 37(5):1812-1828. PubMed ID: 32246264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies.
    Martinez FJ; Rabe KF; Lipworth BJ; Arora S; Jenkins M; Martin UJ; Reisner C
    Int J Chron Obstruct Pulmon Dis; 2020; 15():99-106. PubMed ID: 32021148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global Initiative for Chronic Obstructive Lung Disease strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: an Asia-Pacific perspective.
    Asia Pacific COPD Roundtable Group
    Respirology; 2005 Jan; 10(1):9-17. PubMed ID: 15691232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COPD-X Australian and New Zealand guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 2017 update.
    Yang IA; Brown JL; George J; Jenkins S; McDonald CF; McDonald VM; Phillips K; Smith BJ; Zwar NA; Dabscheck E
    Med J Aust; 2017 Nov; 207(10):436-442. PubMed ID: 29129177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A brief history of pulmonary rehabilitation.
    Casaburi R
    Respir Care; 2008 Sep; 53(9):1185-9. PubMed ID: 18718037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study.
    Wang C; Xu J; Yang L; Xu Y; Zhang X; Bai C; Kang J; Ran P; Shen H; Wen F; Huang K; Yao W; Sun T; Shan G; Yang T; Lin Y; Wu S; Zhu J; Wang R; Shi Z; Zhao J; Ye X; Song Y; Wang Q; Zhou Y; Ding L; Yang T; Chen Y; Guo Y; Xiao F; Lu Y; Peng X; Zhang B; Xiao D; Chen CS; Wang Z; Zhang H; Bu X; Zhang X; An L; Zhang S; Cao Z; Zhan Q; Yang Y; Cao B; Dai H; Liang L; He J;
    Lancet; 2018 Apr; 391(10131):1706-1717. PubMed ID: 29650248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological approach and adherence to treatment recommendations in frequently and non-frequently exacerbating COPD patients from Italy: MISTRAL - The prospective cohort, observational study.
    Scalone G; Nava S; Ventrella F; Bussoli G; Catapano GA; Pennisi A; Dadduzio F; Schino P; Pela R; Bartezaghi M; Morini P; Porpiglia PA; Muscianisi E;
    Pulm Pharmacol Ther; 2018 Dec; 53():68-77. PubMed ID: 30193866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhaled treatment of COPD: a Delphi consensus statement.
    Ninane V; Corhay JL; Germonpré P; Janssens W; Joos GF; Liistro G; Vincken W; Gurdain S; Vanvlasselaer E; Lehouck A
    Int J Chron Obstruct Pulmon Dis; 2017; 12():793-801. PubMed ID: 28293106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Update on the Global Initiative for Chronic Obstructive Lung Disease 2017 Guidelines With a Focus on Classification and Management of Stable COPD.
    Burkes RM; Donohue JF
    Respir Care; 2018 Jun; 63(6):749-758. PubMed ID: 29794208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teaching inhalation technique in COPD outpatients: Can a sustained improvement be achieved?
    Duarte-de-Araújo A; Teixeira P; Hespanhol V; Correia-de-Sousa J
    Pulmonology; 2019; 25(1):53-55. PubMed ID: 30772262
    [No Abstract]   [Full Text] [Related]  

  • 11. Guideline for the management of chronic obstructive pulmonary disease (COPD): 2004 revision.
    Bateman ED; Feldman C; O'Brien J; Plit M; Joubert JR;
    S Afr Med J; 2004 Jul; 94(7 Pt 2):559-75. PubMed ID: 15283307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology, severity, and treatment of chronic obstructive pulmonary disease in the United Kingdom by GOLD 2013.
    Raluy-Callado M; Lambrelli D; MacLachlan S; Khalid JM
    Int J Chron Obstruct Pulmon Dis; 2015; 10():925-37. PubMed ID: 25999708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of the tiotropium/olodaterol inhaler for patients with chronic obstructive pulmonary disease.
    Ferguson GT; Dalby RN
    Postgrad Med; 2018 Aug; 130(6):515-522. PubMed ID: 29972656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tiotropium in Early-Stage Chronic Obstructive Pulmonary Disease.
    Zhou Y; Zhong NS; Li X; Chen S; Zheng J; Zhao D; Yao W; Zhi R; Wei L; He B; Zhang X; Yang C; Li Y; Li F; Du J; Gui J; Hu B; Bai C; Huang P; Chen G; Xu Y; Wang C; Liang B; Li Y; Hu G; Tan H; Ye X; Ma X; Chen Y; Hu X; Tian J; Zhu X; Shi Z; Du X; Li M; Liu S; Yu R; Zhao J; Ma Q; Xie C; Li X; Chen T; Lin Y; Zeng L; Ye C; Ye W; Luo X; Zeng L; Yu S; Guan WJ; Ran P
    N Engl J Med; 2017 Sep; 377(10):923-935. PubMed ID: 28877027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of tiotropium on hyperinflation and treadmill exercise tolerance in mild to moderate chronic obstructive pulmonary disease.
    Casaburi R; Maltais F; Porszasz J; Albers F; Deng Q; Iqbal A; Paden HA; O'Donnell DE;
    Ann Am Thorac Soc; 2014 Nov; 11(9):1351-61. PubMed ID: 25289942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis.
    Hurst JR; Dilleen M; Morris K; Hills S; Emir B; Jones R
    Int J Chron Obstruct Pulmon Dis; 2018; 13():781-792. PubMed ID: 29551894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COPD: misuse of inhaler devices in clinical practice.
    Duarte-de-Araújo A; Teixeira P; Hespanhol V; Correia-de-Sousa J
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1209-1217. PubMed ID: 31213798
    [No Abstract]   [Full Text] [Related]  

  • 18. Chronic obstructive pulmonary disease--a treatable disease.
    Osthoff M; Jenkins C; Leuppi J
    Swiss Med Wkly; 2013; 143():w13777. PubMed ID: 23592218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy.
    Moretz C; Hahn B; White J; Goolsby Hunter A; Essoi B; Elliott C; Ray R
    Int J Chron Obstruct Pulmon Dis; 2020; 15():2715-2725. PubMed ID: 33149569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study.
    Ferguson GT; Tashkin DP; Skärby T; Jorup C; Sandin K; Greenwood M; Pemberton K; Trudo F
    Respir Med; 2017 Nov; 132():31-41. PubMed ID: 29229103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.